A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Kaya Holdings, Inc is a holding company focusing on wellness and mental health through operations in psychedelic treatment clinics, medical and recreational cannabis, and CBD products. In 2014, KAYS became the first US public company to own and operate a medical cannabis dispensary in the United States and has again broken ground with the licensing and opening in August 2024 of The Sacred Mushroom Psychedelic Treatment Center in Portland, Oregon. KAYS is operating The Sacred Mushroom as part of its Fifth Dimension Therapeutics, Inc. subsidiary (“FDT”), which also intends to work cooperatively with select pharmaceutical companies to maximize the curative and therapeutic potential of psilocybin. KAYS has approximately ten years of operational experience as a vertically integrated legal cannabis enterprise both operating legal marijuana dispensaries, as well as cultivation and manufacturing facilities.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | -1K | - | - | - | - | - |
| Net Income | -12M | -2.1M | 1.6M | -3.6M | 9.7M | 12M |
| EPS | $-0.10 | $-0.07 | $0.01 | $-0.16 | $0.66 | $-0.92 |
| Free Cash Flow | 0 | -858K | -1.2M | -931K | -1.1M | -321K |
| ROIC | -788.9% | -738.3% | -467.2% | -160.3% | -84.1% | -79.8% |
| Gross Margin | - | 0.0% | - | - | - | 0.0% |
| Debt/Equity | 0.00 | -0.02 | -0.53 | -0.00 | -0.48 | -0.00 |
| Dividends/Share | $0.00 | $0.00 | - | - | - | $0.00 |
| Operating Income | -821K | -2.0M | -1.0M | -1.7M | -1.4M | -1.8M |
| Operating Margin | 0.0% | 0.0% | - | - | - | 0.0% |
| ROE | 0.0% | 0.0% | - | - | - | 0.0% |
| Shares Outstanding | 686M | 30M | 22M | 22M | 15M | 14M |
Kaya Holdings, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Kaya Holdings, Inc. trades at 0.4x trailing earnings, compared to its 15-year median P/E of 0.5x, suggesting it is currently Fair relative to its historical range. At current prices, the estimated annualized return to fair value is -32.0%.
Kaya Holdings, Inc. (KAYS) has a current P/E ratio of 0.4, compared to its historical median P/E of 0.5. The stock is currently considered Fair based on its historical valuation range.
Kaya Holdings, Inc. (KAYS) has a 5-year average return on invested capital (ROIC) of -108.1%. This is below average and may indicate limited pricing power.
Kaya Holdings, Inc. (KAYS) has a market capitalization of $22M. It is classified as a small-cap stock.
Kaya Holdings, Inc. (KAYS) does not currently pay a regular dividend.
Based on historical P/E analysis, Kaya Holdings, Inc. (KAYS) appears fair. The current P/E of 0.4 is 3% below its historical median of 0.5. The estimated fair value CAGR (P/E method) is -32.0%.
Kaya Holdings, Inc. (KAYS) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Kaya Holdings, Inc. (KAYS) generated $-858 thousand in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Kaya Holdings, Inc. (KAYS) reported earnings per share (EPS) of $-0.07 in its most recent fiscal year.
The Ledger Terminal provides 13 years of financial data for Kaya Holdings, Inc. (KAYS), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Kaya Holdings, Inc. (KAYS) has a book value per share of $-0.51, based on its most recent annual SEC filing.
No recent press releases.